|
|
|
|
|
|
Sponsors and Collaborators: |
Sheba Medical Center University Hospital Goettingen Carmel Medical Center |
Information provided by: | Sheba Medical Center |
ClinicalTrials.gov Identifier: | NCT00449306 |
Lipid-rich atherosclerotic plaques, or "vulnerable plaques" are prone to rupture, causing local intravascular thrombosis, with subsequent grave clinical consequences. Atherosclerotic plaques normally removed during surgery, and peripheral blood samples will be studied to achieve the following objectives:
"1" Define histological features of the vulnerable plaque, analyze its physical characteristics, and investigate selected gene expression.
"2" Study biomarkers of inflammation in conjunction with the presence of vulnerable plaques.
"3" Explore the potential role of infection in atherogenesis.
Condition |
Atherosclerosis Aortic Aneurysm Peripheral Vascular Diseases |
MedlinePlus related topics: | Aneurysms Peripheral Arterial Disease Vascular Diseases |
Drug Information available for: | Lipids |
Study Type: | Observational |
Study Design: | Case Control, Cross-Sectional |
Official Title: | Physical,Histological,and Genetic Analyses of Lipid-Rich Atherosclerotic Plaques |
Tissue for RNA extraction (frozen); Tissue for histological analysis (formalin fixation); Plasma for CV biomarkers (frozen)
Estimated Enrollment: | 120 |
Study Start Date: | March 2001 |
Estimated Study Completion Date: | January 2010 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Primary Care Clinic patients
Inclusion Criteria:
Exclusion Criteria:
Contact: Jacob Schneiderman, MD | 972 3 5302712 | jschneid@netvision.net.il |
Israel | |||||
Sheba Medical Center, Tel Hashomer | Recruiting | ||||
Ramat Gan, Israel, 52621 | |||||
Contact: Jacob Schneiderman, MD 972 3 5302712 jschneid@netvision.net.il |
Sheba Medical Center |
University Hospital Goettingen |
Carmel Medical Center |
Principal Investigator: | Jacob Schneiderman, MD | Department of Vascular Surgery, Sheba Medical Center, Tel Hashomer |
Responsible Party: | Sheba Medical Cener ( Dr. Jacob Schneiderman ) |
Study ID Numbers: | SHEBA-01-2354-JS-CTIL |
First Received: | March 19, 2007 |
Last Updated: | March 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00449306 |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
|
|
|
|
|